FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080512616> ?p ?o ?g. }

• W2080512616 endingPage "799" @default.
• W2080512616 startingPage "797" @default.
• W2080512616 abstract "Hepatic hydroxymethyl glutaryl–CoA reductase inhibitors, known as statins, are among the most commonly prescribed drugs in the world. Scientists studying microorganism host defense first identified statins in the 1970s. They were eventually shown in large randomized trials, such as the Scandinavian Simvastatin Survival Study and the West of Scotland Coronary Prevention Study, to confer substantial clinical benefits over placebo in individuals with hypercholesterolemia. Statins are now a cornerstone for both primary and secondary prevention of coronary heart disease. A number of noncardiovascular benefits—such as in dementia, sepsis, and cancer—have also been proposed, largely on the basis of observational data. In this issue of JASN, Molnar et al.1 report the results of an observational study on the association between statin use and decreased incidence of perioperative acute kidney injury (AKI) and mortality. The population-based cohort contained data on 213,347 Ontario Drug Benefits Plan recipients who were aged ≥66 years and underwent elective cardiac, thoracic, vascular, abdominal, or retroperitoneal surgery between 1995 and 2008. As anticipated, those who received statins tended to have more comorbid atherosclerotic disease, hypertension, diabetes, and congestive heart failure; to be treated with a greater number of total and cardiovascular-related medications; to have undergone more extensive cardiovascular diagnostic evaluations and procedures; and more likely to be undergoing cardiac and vascular surgery. On this basis, unadjusted analyses demonstrated an increased risk in perioperative AKI and dialysis use among statin users. However, upon multivariable and propensity score adjustment, statin use was associated with a 14 to 17% reduction in these outcomes. Curiously, unadjusted mortality was 27% lower in the statin group despite greater comorbid disease burden; mortality risk remained 15 to 21% lower after statistical adjustment. Analyses that appropriately accounted for healthier adherer bias and dose-response trends yielded corroborative findings. The population-based cohort design promotes generalizability, although, in fairness, only to elderly patients undergoing elective surgery. As with all research on humans, internal validity of findings is contingent on accurate characterization of events and conditions. Absent available laboratory data, AKI was characterized solely on the basis of diagnostic codes. Considering the cohort's era, the majority of hospitalizations would have been coded using the International Classification of Diseases, Ninth Revision classification system, which has only 28.3% sensitivity for AKI.2 Moreover, chronic kidney disease (CKD)—arguably the most important covariate—was assessed with only 22.9% sensitivity and 87.5% specificity (Appendix D-2).1 Thus, both the outcome and a critical covariate had substantial error rates. An often-repeated mantra in epidemiologic research is that nondifferential misclassification biases toward the null hypothesis. In other words, if information on AKI or CKD or other covariates were inaccurate but randomly so, then a study would tend to find no association even if an association existed and would therefore not account for the protective association seen in this study. However, this is an oversimplification for at least two reasons. First, if errors in diagnostic codes were correlated—that is, errors in AKI codes were more common in those with errors in CKD codes, such as might occur for patients with limited medical follow-up—then measures of association could be biased in either direction.3 Second, we previously showed that AKI diagnostic codes in fact suffer from relevant nondifferential misclassification: codes have higher sensitivity in men than in women, in the elderly, and in those who die in-hospital.2 To the extent that statin use in the Ontario cohort differed by race, gender, and mortality, misclassification bias cannot be ignored. As with any observational study, the potential for causal inference must also be interpreted in light of the underlying biological basis and literature precedent. Studies of animal models demonstrated that statin use is associated with a decreased risk for ischemia-reperfusion kidney injury. Proposed mechanisms include favorable effects on oxidative metabolism involving heme oxygenase 1, NF-κB, activator protein 1, mevalonate, and nitric oxide.4–7 However, animal data do not invariably translate to clinical practice. For example, N-acetyl cysteine showed similar promise in preclinical models yet demonstrated little to no clinical efficacy in preventing perioperative AKI.8–10 In addition, any cogent attempt to rationalize the study's findings as causal should account for the graded trend toward incrementally better outcomes among patients exposed to statins for shorter periods (adjusted odds ratios 0.86, 0.77, and 0.61 for statin use >90, 30 to 90, and <30 days, respectively), which does not follow intuitively on the basis of the proposed mechanism and may instead signal residual confounding. The plausibility of the magnitude of the observed benefits also needs to be considered in light of previous studies. Molnar et al.1 report a striking 21% lower odds of death, which is comparable to—or greater than—effects sizes seen in placebo-controlled trials of statins in patients at cardiovascular risk; that is, those with hypercholesterolemia and previous coronary heart disease. It is hard to imagine that the mortality benefit of statins in this population-based study could equal or exceed that seen in populations with high cardiovascular risk. Notwithstanding these issues, let us consider the therapeutic implications of the study's findings assuming that estimates are both unbiased and causal. Perioperative AKI was observed in 1.9% of patients. Using the most favorable estimate for the effect of statins (odds ratio 0.84), 1000 patients would need to be treated to avert three instances of AKI. This number treated would avert fewer than one episode of dialysis-requiring AKI. At the same time, estimates from the literature suggest that such treatment would result in approximately four cases of aminotransferase elevation,11 as well as a heightened risk for myalgias, myopathy, and rhabdomyolysis.12 Furthermore, informed assessment of the net health benefits of perioperative statin renal prophylaxis would require simultaneous consideration of permanent renal injury; that is, residual CKD or ESRD and sequelae thereof. Although the article does not address this specifically, absence of association between statin use and reduced dialysis dependence 90 to 120 days postoperatively may be cause for pessimism vis-à-vis long-term renal benefit. Alternatively, it is possible that perioperative renal prophylaxis with statins could be targeted to patients at high risk for perioperative AKI, for whom the risk-benefit ratio might be more favorable. However, the data at hand cannot provide supportive evidence for such a paradigm given that subgroup analyses restricted to those at highest risk– for example, patients with diabetes and those with pre-existing CKD– were not performed. As the authors note, sample size requirements likely preclude the possibility that a dedicated, hard end point, randomized trial will ever be conducted. Considering residual uncertainties, we wonder whether a smaller randomized trial using kidney injury biomarker surrogate end points might be warranted. Would the finding of lower kidney injury biomarker levels postoperatively in patients randomly assigned to statins versus placebo provide sufficient evidence to justify widespread use of statins overall or in high-risk patients? Possibly, but consider the instructive story of torcetrapib, which increased HDL levels but also increased the risk for death in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerosis Events (ILLUMINATE) trial.13 Approval of torcetrapib on the basis of improvement in a biologically plausible but untested surrogate end point would have been a catastrophic failure.14 Although the U.S. Food and Drug Administration and other international regulatory agencies have qualified several kidney injury biomarkers for preclinical nephrotoxicity monitoring,15 it remains unclear whether and in which contexts novel biomarkers may be acceptable surrogate end points for AKI trials. At the very least, follow-up observational studies using cohorts with available laboratory data are needed before clinical adoption. To summarize, Molnar et al.1 have produced a careful analysis of a large data set suggesting an association between statin use and lower risk for postoperative AKI. Unfortunately, potentially insurmountable limitations related to confounding by indication and differential misclassification of exposure and outcome status render the findings insufficiently persuasive to warrant adoption into clinical practice despite the rigor of the authors' analytic approach. Barring corroborative findings in other studies, this analysis may be relegated to be yet another footnote in the long, sad saga of failed AKI therapeutics. DISCLOSURES None." @default.
• W2080512616 created "2016-06-24" @default.
• W2080512616 creator A5025097124 @default.
• W2080512616 creator A5064518665 @default.
• W2080512616 date "2011-05-01" @default.
• W2080512616 modified "2023-10-16" @default.
• W2080512616 title "Peri-surgical Statins Lessen Acute Kidney Injury" @default.
• W2080512616 cites W1976998942 @default.
• W2080512616 cites W2002641335 @default.
• W2080512616 cites W2003418600 @default.
• W2080512616 cites W2029199491 @default.
• W2080512616 cites W2035491556 @default.
• W2080512616 cites W2048760408 @default.
• W2080512616 cites W2051160165 @default.
• W2080512616 cites W2074510873 @default.
• W2080512616 cites W2103846010 @default.
• W2080512616 cites W2103873642 @default.
• W2080512616 cites W2109003787 @default.
• W2080512616 cites W2113101136 @default.
• W2080512616 cites W2123504070 @default.
• W2080512616 cites W2126332577 @default.
• W2080512616 cites W2165192883 @default.
• W2080512616 doi "https://doi.org/10.1681/asn.2011020186" @default.
• W2080512616 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21493777" @default.
• W2080512616 hasPublicationYear "2011" @default.
• W2080512616 type Work @default.
• W2080512616 sameAs 2080512616 @default.
• W2080512616 citedByCount "4" @default.
• W2080512616 countsByYear W20805126162012 @default.
• W2080512616 countsByYear W20805126162013 @default.
• W2080512616 countsByYear W20805126162015 @default.
• W2080512616 crossrefType "journal-article" @default.
• W2080512616 hasAuthorship W2080512616A5025097124 @default.
• W2080512616 hasAuthorship W2080512616A5064518665 @default.
• W2080512616 hasBestOaLocation W20805126161 @default.
• W2080512616 hasConcept C126322002 @default.
• W2080512616 hasConcept C126894567 @default.
• W2080512616 hasConcept C141071460 @default.
• W2080512616 hasConcept C177713679 @default.
• W2080512616 hasConcept C2778374610 @default.
• W2080512616 hasConcept C2780472472 @default.
• W2080512616 hasConcept C31174226 @default.
• W2080512616 hasConcept C71924100 @default.
• W2080512616 hasConceptScore W2080512616C126322002 @default.
• W2080512616 hasConceptScore W2080512616C126894567 @default.
• W2080512616 hasConceptScore W2080512616C141071460 @default.
• W2080512616 hasConceptScore W2080512616C177713679 @default.
• W2080512616 hasConceptScore W2080512616C2778374610 @default.
• W2080512616 hasConceptScore W2080512616C2780472472 @default.
• W2080512616 hasConceptScore W2080512616C31174226 @default.
• W2080512616 hasConceptScore W2080512616C71924100 @default.
• W2080512616 hasIssue "5" @default.
• W2080512616 hasLocation W20805126161 @default.
• W2080512616 hasLocation W20805126162 @default.
• W2080512616 hasLocation W20805126163 @default.
• W2080512616 hasOpenAccess W2080512616 @default.
• W2080512616 hasPrimaryLocation W20805126161 @default.
• W2080512616 hasRelatedWork W2150604099 @default.
• W2080512616 hasRelatedWork W2354785620 @default.
• W2080512616 hasRelatedWork W2415364279 @default.
• W2080512616 hasRelatedWork W2586998360 @default.
• W2080512616 hasRelatedWork W2767618185 @default.
• W2080512616 hasRelatedWork W2915547445 @default.
• W2080512616 hasRelatedWork W4226412087 @default.
• W2080512616 hasRelatedWork W4324096639 @default.
• W2080512616 hasRelatedWork W4324357392 @default.
• W2080512616 hasRelatedWork W4210320650 @default.
• W2080512616 hasVolume "22" @default.
• W2080512616 isParatext "false" @default.
• W2080512616 isRetracted "false" @default.
• W2080512616 magId "2080512616" @default.
• W2080512616 workType "article" @default.